Filing Details
- Accession Number:
- 0001209191-16-115079
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-04-20 17:49:11
- Reporting Period:
- 2016-04-18
- Filing Date:
- 2016-04-20
- Accepted Time:
- 2016-04-20 17:49:11
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1328143 | Adamas Pharmaceuticals Inc | ADMS | Pharmaceutical Preparations (2834) | 421560076 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1604572 | Natalie Mcclure | C/O Adamas Pharmaceuticals, Inc. 1900 Powell St., Suite 750 Emeryville CA 94608 | Svp, Product Development | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-04-18 | 12,666 | $1.76 | 21,006 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-04-18 | 12,666 | $18.50 | 8,340 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2016-04-18 | 23,334 | $0.67 | 31,674 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-04-18 | 23,334 | $18.50 | 8,340 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2016-04-18 | 12,666 | $0.00 | 12,666 | $1.76 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2016-04-18 | 23,334 | $0.00 | 23,334 | $0.67 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2020-03-03 | No | 4 | M | Direct | |
16,666 | 2021-11-16 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- This option is fully vested and exercisable.
- The Option shares shall vest as follows: one-fifth (1/5th) of the shares vest one year after June 30, 2011; the balance of the shares vest in a series of forty-eight (48) successive equal monthly installments measured from the first anniversary of June 30, 2011, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.